# Psychiatric safety and metabolic effects of GLP-1 receptor agonists in antipsychotic-induced weight gain: a meta-analysis of randomized controlled trials - URL: https://alisanburak.com/en/wcp-2026-posterler/so064 - Language: en - Last updated: not specified - Page title: Psychiatric safety and metabolic effects of GLP-1 receptor agonists in antipsychotic-induced weight gain: a meta-analysis of randomized controlled trials | WCP 2026 Summary > GLP-1 receptor agonists significantly reduced weight, BMI, waist circumference, and HbA1c in patients with antipsychotic-induced weight gain, with no evidence… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/so064) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. SO064 Brief Oral Poster PresentationPsychopharmacologyMeta-analysis # Psychiatric safety and metabolic effects of GLP-1 receptor agonists in antipsychotic-induced weight gain: a meta-analysis of randomized controlled trials PSYCHIATRIC SAFETY AND METABOLIC EFFECTS OF GLP-1 RECEPTOR AGONISTS FOR ANTIPSYCHOTIC INDUCED WEIGHT GAIN: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Presenter: Gabriela Melcop de Castro Leal Dantas Country: Brazil Institution: Independent Researcher Session: 2760 - PARALLEL SHORT ORAL POSTER SESSIONS: MISCELLANEOUS - Part II Date: Thu, 24.09.2026 GLP-1 receptor agonists significantly reduced weight, BMI, waist circumference, and HbA1c in patients with antipsychotic-induced weight gain, with no evidence of worsening psychiatric symptoms. The aim was to evaluate the metabolic efficacy and psychiatric safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in adults taking second-generation antipsychotics who had developed antipsychotic-induced weight gain (AIWG). This systematic review and meta-analysis, conducted in accordance with the PRISMA 2020 guidelines, searched for randomized controlled trials (RCTs) comparing GLP-1 RAs with placebo; 377 studies were assessed, and 8 studies with a total of 523 participants were included (257 in the GLP-1 RA arm; 45% male, median age 35.3 years, follow-up 12 to 40 weeks). Of the sample, 83% had a diagnosis of schizophrenia and 6% had schizoaffective disorder; the most commonly used antipsychotics were clozapine in 226 participants (40%), olanzapine in 133 (23%), and quetiapine in 73 (13%). Continuous outcomes were pooled using a random-effects model as mean differences (MDs) or standardized mean differences (SMDs). No between-group difference in psychiatric symptom severity was found (SMD -0.04; 95% CI -0.49 to 0.41; p=0.81); the reported estimates were -0.13 for positive symptoms (-0.33 to 0.07; p=0.14), 0.44 for PANSS total score (-2.31 to 3.19; p=0.56), -0.42 for PANSS positive score (-1.41 to 0.57; p=0.21), and 0.99 for PANSS negative score (-3.11 to 5.09; p=0.41). Anthropometric outcomes showed reductions in body weight, with an MD of -6.54 kg (95% CI -10.43 to -2.65; p=0.005), BMI of -2.36 kg/m2 (-3.42 to -1.30; p=0.001), and waist circumference of -4.47 cm (-6.38 to -2.55; p=0.001). For glycemic outcomes, HbA1c decreased by -0.32 (-0.43 to -0.21; p=0.0004), while serum glucose showed no significant change (-3.17 mmol/L; -8.54 to 2.20; p=0.25). In conclusion, GLP-1 RAs improve metabolic outcomes in patients with AIWG and, based on the available data, do not lead to worsening psychiatric symptoms; this finding supports the use of these medications in patients with severe mental illness and high cardiometabolic risk. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/643) How to cite this study APA 7: Dantas, G. M. D. C. L., et al. (2026, September 24). Psychiatric safety and metabolic effects of glp-1 receptor agonists for antipsychotic induced weight gain: a meta-analysis of randomized controlled trials [Poster presentation]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/643 Vancouver: Dantas GMDCL, et al. Psychiatric safety and metabolic effects of glp-1 receptor agonists for antipsychotic induced weight gain: a meta-analysis of randomized controlled trials [poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/643 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/so064 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim